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A bs tr ac t
Background
Patients with cirrhosis in Child–Pugh class C or those in class B who have persistent 
bleeding at endoscopy are at high risk for treatment failure and a poor prognosis, 
even if they have undergone rescue treatment with a transjugular intrahepatic porto-
systemic shunt (TIPS). This study evaluated the earlier use of TIPS in such patients.
Methods
We randomly assigned, within 24 hours after admission, a total of 63 patients with 
cirrhosis and acute variceal bleeding who had been treated with vasoactive drugs 
plus endoscopic therapy to treatment with a polytetrafluoroethylene-covered stent 
within 72 hours after randomization (early-TIPS group, 32 patients) or continuation 
of vasoactive-drug therapy, followed after 3 to 5 days by treatment with propranolol 
or nadolol and long-term endoscopic band ligation (EBL), with insertion of a TIPS 
if needed as rescue therapy (pharmacotherapy–EBL group, 31 patients).
Results
During a median follow-up of 16 months, rebleeding or failure to control bleeding 
occurred in 14 patients in the pharmacotherapy–EBL group as compared with 1 pa-
tient in the early-TIPS group (P = 0.001). The 1-year actuarial probability of remain-
ing free of this composite end point was 50% in the pharmacotherapy–EBL group 
versus 97% in the early-TIPS group (P<0.001). Sixteen patients died (12 in the phar-
macotherapy–EBL group and 4 in the early-TIPS group, P = 0.01). The 1-year actu-
arial survival was 61% in the pharmacotherapy–EBL group versus 86% in the early-
TIPS group (P<0.001). Seven patients in the pharmacotherapy–EBL group received 
TIPS as rescue therapy, but four died. The number of days in the intensive care unit 
and the percentage of time in the hospital during follow-up were significantly higher 
in the pharmacotherapy–EBL group than in the early-TIPS group. No significant dif-
ferences were observed between the two treatment groups with respect to serious 
adverse events.
Conclusions
In these patients with cirrhosis who were hospitalized for acute variceal bleeding 
and at high risk for treatment failure, the early use of TIPS was associated with sig-
nificant reductions in treatment failure and in mortality. (Current Controlled Trials 
number, ISRCTN58150114.)
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Variceal bleeding is a severe compli-cation of portal hypertension and a major cause of death in patients with cirrhosis. 
Advanced liver failure, failure to control variceal 
bleeding, early rebleeding, and marked elevations 
in portal pressure are associated with increased 
mortality.1-3 Combined treatment with vasoactive 
drugs, prophylactic antibiotics, and endoscopic 
techniques is the recommended standard of care 
for patients with acute variceal bleeding.4,5 How-
ever, treatment failure occurs in about 10 to 15% 
of patients,6,7 who require repeat endoscopic treat-
ments and multiple transfusions.8-10 Treatment 
with a transjugular intrahepatic portosystemic 
shunt (TIPS) is highly effective in the control of 
bleeding in such patients, but mortality is still very 
high,9 probably because of further deterioration 
due to liver failure.
In a study involving patients at high risk for 
treatment failure, as indicated by a hepatic venous 
pressure gradient of 20 mm Hg or more,11 early 
treatment with TIPS improved the prognosis in 
comparison with medical treatment in a study by 
Monescillo et al.12 However, the treatment ad-
ministered in the medical-treatment group was not 
the current standard of care,12 which may have 
resulted in a worse outcome than expected in this 
group.
We conducted a study to determine whether 
early treatment with TIPS, with the use of a stent 
covered with extended polytetrafluoroethylene 
(e-PTFE), can improve outcomes in patients with 
cirrhosis and variceal bleeding who are at high 
risk for treatment failure and death.
Me thods
Selection of Patients
We enrolled patients at nine European centers (see 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org) between May 
2004 and March 2007. Eligible patients had cir-
rhosis with acute esophageal variceal bleeding 
that was being treated with a combination of va-
soactive drugs, endoscopic treatment, and pro-
phylactic antibiotics. Patients had Child–Pugh 
class C disease (a score of 10 to 13) or they had 
class B disease (a score of 7 to 9) but with active 
bleeding at diagnostic endoscopy. Patients with 
scores higher than 13 were excluded from the 
study. (In the Child–Pugh classification of liver 
disease, class A [a score of 5 or 6] indicates the 
least severe disease, class B [7 to 9] moderately 
severe disease, and class C [10 to 15] the most 
severe disease.) Endoscopic band ligation (EBL) 
or endoscopic injection sclerotherapy (EIS) was 
applied at the time of diagnostic endoscopy, per-
formed within 12 hours after admission, while the 
patients were already receiving vasoactive drugs 
(terlipressin [2 mg every 4 hours], somatostatin 
[250 to 500 μg per hour], or octreotide [50 to 100 
μg per hour]). Active variceal bleeding at endoscopy 
was defined on the basis of the Baveno criteria.13
Exclusion criteria were an age of more than 
75 years, pregnancy, hepatocellular carcinoma that 
did not meet the Milano criteria for transplanta-
tion (i.e., a single lesion <5 cm or multiple lesions 
[maximum of three], the largest of which mea-
sures ≤3 cm), a creatinine level greater than 3 mg 
per deciliter (265 μmol per liter), a Child–Pugh 
score above 13 points, previous pharmacologic 
therapy combined with endoscopic treatment to 
prevent rebleeding, previous use of a portosys-
temic shunt or TIPS, bleeding from isolated gas-
tric or ectopic varices, total portal-vein thrombo-
sis, and heart failure.
All patients provided written informed consent. 
The study protocol was approved by the ethics 
committees of all participating hospitals and fol-
lowed the Guidelines for Good Clinical Practice 
in clinical trials.
Study Design
Randomization was performed within 24 hours 
after admission. The randomization sequence was 
generated by computer with the use of a concealed 
block size of four. The coded treatment assign-
ments were kept at the coordinating center in 
sealed, consecutively numbered, opaque envelopes. 
Randomized assignments to the study groups were 
made by contacting the coordinating center (avail-
able 24 hours a day) by telephone or fax.
Drug Therapy plus EBL
Treatment with vasoactive drugs was continued 
until patients were free of bleeding for at least 24 
hours and preferably up to 5 days, at which point 
treatment with a nonselective beta-blocker (either 
propranolol or nadolol) was started. The dose was 
increased in a stepwise fashion every 2 to 3 days 
to the maximum tolerated dose or to a maximum 
of 160 mg twice daily for propranolol and 240 mg 
per day for nadolol. After these doses were 
achieved, 10 mg of isosorbide-5-mononitrate was 
initiated at bedtime, with a stepwise increase in 
the dose to a maximum of 20 mg twice a day or 
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the maximum tolerated dose. In addition, within 
7 to 14 days after the initial endoscopic treatment, 
the second, elective session of EBL was performed. 
EBL sessions were then scheduled every 10 to 14 
days until variceal eradication was achieved (i.e., 
varices disappeared or could not be suctioned into 
the banding device).
EBL sessions were performed with the use of 
multiband devices (6-Shooter Saeed Multi-Band 
Ligator, Cook, or Speedband SuperView Super 7, 
Boston Scientific), and bands were applied start-
ing at the gastroesophageal junction. Patients 
received proton-pump inhibitors until variceal 
eradication was accomplished. After eradication, 
endoscopic monitoring was performed at 1-month, 
6-month, and 12-month intervals and then an-
nually. If varices reappeared, further EBL sessions 
were initiated.
Treatment failure was defined as one severe 
rebleeding episode (i.e., requiring a transfusion of 
more than 2 units of blood) or two, less severe 
rebleeding episodes,13 with TIPS and placement of 
an e-PTFE–covered stent used as rescue therapy 
when necessary.
Early TIPS
TIPS was performed within 72 hours after diag-
nostic endoscopy (or, when possible, within the 
first 24 hours), and vasoactive drugs were admin-
istered until then. The e-PTFE–covered stents 
(we purchased Viatorr TIPS endoprosthesis, Gore) 
were initially dilated to 8 mm. If the portal-pres-
sure gradient (the difference between portal-vein 
pressure and inferior vena caval pressure) did not 
decrease to below 12 mm Hg, the stent was dilated 
to 10 mm.
TIPS revision was performed if there was clini-
cal recurrence of portal hypertension or evidence 
of TIPS dysfunction on Doppler ultrasonography 
(i.e., portal blood-flow velocity of <28 cm per sec-
ond, a change in the direction of flow in intra-
hepatic portal branches, or a drop in portal blood-
flow velocity of >50%).14 If TIPS dysfunction was 
confirmed, angioplasty was performed or another 
e-PTFE–covered stent was placed.
Follow-up
Follow-up visits were scheduled at 1 month, at 
3 months, and every 3 months thereafter. Doppler 
ultrasonography was performed at the first visit, 
at 6 months, and every 6 months thereafter. Pa-
tients were followed until death or liver trans-
plantation up to a maximum of 2 years of follow-up 
or until the end of the study (September 2007).
Study End Points
The primary end point of the study was a compos-
ite outcome of failure to control acute bleeding or 
failure to prevent clinically significant variceal re-
bleeding within 1 year after enrollment. Second-
ary end points were mortality at 6 weeks and at 
1 year, failure to control acute bleeding, early re-
bleeding (rate of rebleeding at 5 days and at 
6 weeks), rate of rebleeding between 6 weeks and 
1 year, the development of other complications re-
lated to portal hypertension on follow-up, the num-
ber of days in the intensive care unit, the percent-
age of follow-up days spent in the hospital, and 
the use of alternative treatments.
Statistical Analysis
In a study by Villanueva et al. involving patients 
with active variceal bleeding at endoscopy, the rate 
of failure to control bleeding within 5 days, de-
spite the combined use of drugs plus endoscopic 
treatment, was 27%.15 Similarly, the rate of fail-
ure was 23% in a study involving patients with 
Child–Pugh class B or C disease who received com-
bined pharmacologic and endoscopic treatment.16 
We assumed in our population a 25% rate of fail-
ure to control bleeding at 5 days. Considering that 
rebleeding occurred between day 5 and 1 year in 
an additional 20%,6,17 the cumulative rate of fail-
ure to control bleeding or rebleeding at 1 year was 
estimated to be 45%. We hypothesized that this 
risk would be reduced to 10% by an early decision 
to use e-PTFE–covered TIPS. Because the only ra-
tionale for early use of TIPS would be evidence 
that this approach is better than the current stan-
dard treatment, the sample size was calculated 
with the use of a one-sided test.18,19 We calcu-
lated that 31 patients per group would be needed 
to detect these differences, with an alpha level of 
0.05 and a beta level of 0.20.
All data analyses were performed on an inten-
tion-to-treat basis according to a preestablished 
analysis plan. Dichotomous variables were com-
pared by means of Fisher’s exact test, and con-
tinuous variables were compared by means of the 
nonparametric Mann–Whitney rank-sum test. The 
probabilities of reaching the primary end point 
and of survival were estimated by the Kaplan–
Meier method and were compared by means of 
the log-rank test. Absolute risk reductions and 
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number needed to treat, with 95% confidence in-
tervals, were calculated as an estimate of the ef-
fect size and its precision. A P value of less than 
0.05 was considered to indicate statistical signifi-
cance, and all tests were two-sided. The statisti-
cal software packages used for the analysis were 
SPSS (version 16.0) and confidence interval analy-
sis (CIA, version 2.1.2, University of Southamp-
ton, United Kingdom).
R esult s
Study Patients
We screened 359 patients with acute variceal 
bleeding who were admitted to the participating 
hospitals for study eligibility. A total of 296 pa-
tients were excluded (Fig. 1), and the remaining 
63 patients were randomly assigned to either the 
pharmacotherapy–EBL group (31 patients) or the 
early-TIPS group (32 patients). There were no sig-
nificant differences in baseline characteristics be-
tween the two groups at the time of entry into 
the study (Table 1). A total of 7 patients (3 in the 
pharmacotherapy–EBL group and 4 in the early-
TIPS group) were lost to follow-up after a median 
of 8 months (range, 0.5 to 12) without reaching 
the composite end point. The mean (±SD) follow-
up period was 10.6±9.9 months in the pharmaco-
therapy–EBL group and 14.6±8.4 months in the 
early-TIPS group. A total of 6 patients (2 in the 
pharmacotherapy–EBL group and 4 in the early-
TIPS group) underwent liver transplantation dur-
ing follow-up.
In the pharmacotherapy–EBL group, 22 pa-
tients received propranolol (median dose, 55 mg 
[range, 10 to 160]), and only 3 received nadolol. In 
the remaining 6 patients, nonselective beta-block-
er therapy was not initiated because of failure to 
control bleeding, early rebleeding, or death. In 12 
patients, isosorbide-5-mononitrate was added to 
the nonselective beta-blocker (median dose, 25 mg 
[range, 10 to 40]), but it was not added in 13 pa-
tients because of arterial hypotension, the treat-
ing physician’s preference, or early death. Variceal 
eradication was achieved in 12 patients after a 
median of 2 EBL sessions (range, 1 to 7) without 
rebleeding; in 4 patients, eradication was achieved 
after treatment of a rebleeding episode with ad-
ditional EBL sessions. In the remaining 15 pa-
tients, eradication was not achieved (in 12 because 
63 Underwent randomization
359 Patients were admitted for acute
variceal bleeding
296 Were excluded
18 Declined to participate
72 Were in Child–Pugh Class A
40 Were in Child–Pugh Class B, but did 
not have active bleeding at endoscopy
18 Had Child–Pugh score >13 points
22 Had isolated gastric variceal bleeding
18 Had previous TIPS or drugs+EBL
17 Were older than 75 yr
34 Had hepatocellular carcinoma
20 Had portal-vein thrombosis
9 Had renal failure
6 Had prehepatic portal hypertension
22 Had other reasons
 31 Were assigned to receive drugs+EBL
and were included in the analysis
32 Were assigned to receive early TIPS
and were included in the analysis
Figure 1. Screening and Randomization of Patients.
EBL denotes endoscopic band ligation, and TIPS transjugular intrahepatic portosystemic shunt.
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
Pharmacotherapy–EBL 
Group (N = 31)
Early-TIPS Group 
(N = 32) P Value
Age (yr) 49±6 52±10 0.22
Sex (no. of patients) 0.78
Male 23 21
Female 8 11
Cause of cirrhosis (no. of patients) 0.91
Alcohol 20 22
HCV 5 4
Other 6 6
Active alcoholism (no. of patients) 17 15 0.61
Child–Pugh classification (no. of patients)† 0.99
Class B 16 16
Class C 15 16
Child–Pugh score 9.5±1.8 9.3±1.8 0.66
MELD score‡ 16.9±6.3 15.5±5 0.28
MELD–Na score§ 19±7 17±6 0.25
Ascites (no. of patients) 18 19 0.99
Bilirubin (mg/dl) 4.4±4.9 3.7±4.8 0.34
Albumin (g/liter) 26±7 26±7 0.89
Prothrombin time (%)¶ 50±15 53±15 0.33
Creatinine (mg/dl) 1±0.4 1±0.5 0.59
Previous hepatic encephalopathy (no. of patients) 0 6 0.03
Previous variceal bleeding in the absence of combined  
treatment (no. of patients)
5 11 0.15
Active bleeding at endoscopy (no. of patients) 22 23 0.99
Shock at time of admission (no. of patients) 7 7 0.99
Systolic blood pressure (mm Hg) 111±23 104±18 0.22
Hematocrit on admission (%) 27±8 26±6 0.49
Units of blood transfused before randomization (no.) 2.9±3 2.7±2 0.73
Endoscopic treatment at time of index bleeding  
(no. of patients)
0.17
Band ligation 26 21
Injection sclerotherapy 5 11
Vasoactive-drug therapy at time of index bleeding 
(no. of patients)
0.74
Terlipressin 14 12
Somatostatin 16 18
Octreotide 1 2
* Plus–minus values are means ±SD. To convert the values for bilirubin to micromoles per liter, multiply by 17.1. To con-
vert the values for creatinine to micromoles per liter, multiply by 88.4. HCV denotes hepatitis C virus, and TIPS trans-
jugular intrahepatic portosystemic shunt.
† According to the Child–Pugh classification of liver disease, class A (5 to 6 points) indicates the least severe disease, 
class B (7 to 9 points) moderately severe disease, and class C (10 to 15 points) the most severe disease. Patients 
whose Child–Pugh score exceeded 13 points were not included in the study.
‡ The Model for End-Stage Liver Disease (MELD) score ranges from 6 to 40, with higher scores indicating more severe 
disease.
§ The MELD–Na score ranges from 6 to 40, with higher scores indicating more severe liver disease.
¶ The values shown represent a proportion of the mean prothrombin time in a group of control subjects.
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the primary end point was reached [resulting in 
rescue TIPS in 7 and death in 5], in 2 who were 
lost to follow-up, and in 1 despite eight EBL 
sessions).
In the early-TIPS group, all but 1 patient, who 
withdrew consent, underwent early shunt place-
ment. There were no technical failures or major 
complications of the TIPS procedure. Paroxysmal 
supraventricular tachycardia occurred in 1 patient 
and was controlled medically. A total of 27 pa-
tients required one stent, and 4 required two 
stents. The mean portal-pressure gradient dropped 
from 20.2±7 mm Hg to 6.2±3 mm Hg (P<0.001). 
Despite dilation to 10 mm, the portal-pressure 
gradient after TIPS remained above 12 mm Hg in 
2 patients. Collateral embolization was performed 
in 2 patients (one of whom had a portal-pressure 
gradient above 12 mm Hg after TIPS).
Table 2. Summary of Efficacy Measurements.*
Variable
Pharmacotherapy–EBL 
Group (N = 31)
Early-TIPS Group 
(N = 32) P Value
Composite end point reached (no. of patients) 14 1 0.001
Child–Pugh classification†
Class B 5 0
Class C 9 1
Treatment failure at 5 days‡ 4 1
Rebleeding
>5 days–6 wk 7 0
>6 wk–1 yr 3 0
Minor rebleeding (no. of patients) 3 1 0.35
Gastric ulcer 1
Portal hypertensive gastropathy 1
Varices 1
Post-EBL ulcer 1
Days in intensive care unit (no.) 8.6±9 3.6±4 0.01
Orthotopic liver transplantation (no. of patients) 2 4 0.67
Death (no. of patients) 12 4 0.01 
Child–Pugh classification
Class B 2 1
Class C 10 3
Cause of death
Recurrent bleeding 5 0
Sepsis 4 3
Liver failure 2 0
Hepatorenal syndrome 1 0
Arrhythmia 0 1
Time in hospital (% of follow-up) 0.014 
Median 15 4
Interquartile range 5–100 2–13
* Plus–minus values are means ±SD. EBL denotes endoscopic band ligation, and TIPS transjugular intrahepatic portosys-
temic shunt.
† According to the Child–Pugh classification of liver disease, class A (5 to 6 points) indicates the least severe disease, 
class B (7 to 9 points) moderately severe disease, and class C (10 to 15 points) the most severe disease. Patients 
whose Child–Pugh score exceeded 13 points were not included in the study.
‡ Treatment failure was defined as one severe rebleeding episode (with transfusion requiring more than 2 units of blood) 
or two less severe rebleeding episodes.
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Rebleeding
In the pharmacotherapy–EBL group, 14 patients 
reached the primary composite end point (Table 2 
and Fig. 2). In these patients, the Model for End-
Stage Liver Disease (MELD) score (which ranges 
from 6 to 40, with higher scores indicating more 
severe disease) increased from a mean of 18.8±6.4 
at randomization to 22.6±11 at the time the end 
point was reached. In 7 of these patients, TIPS 
with an e-PTFE–covered stent was used as rescue 
therapy; although bleeding was controlled, 4 of 
these patients died within 36 days (range, 1 to 36). 
In 5 patients, no further treatment was consid-
ered because of severe liver failure, and all died. 
In the 9 patients who died, the mean MELD score 
was 28.2±9 when they reached the primary end 
point of the study. The remaining 2 patients who 
reached the primary end point underwent addi-
tional EBL sessions and were alive at the end of 
the follow-up period.
Only 1 patient in the early-TIPS group, in whom 
the portal-pressure gradient remained above 12 
mm Hg, reached the primary end point (P<0.001 
for the comparison with the pharmacotherapy–
EBL group) (Table 2). The 1-year actuarial proba-
bility of remaining free of failure to control bleed-
ing and of variceal rebleeding was significantly 
higher in the early-TIPS group than in the phar-
macotherapy–EBL group (97% vs. 50%; absolute 
risk reduction, 47 percentage points; 95% confi-
dence interval [CI], 25 to 69; number needed to 
treat, 2.1 patients; 95% CI, 1.4 to 4.0) (Fig. 2). An 
additional 4 patients (3 in the pharmacotherapy–
EBL group and 1 in the early-TIPS group) had a 
rebleeding episode that was not clinically signifi-
cant (i.e., it did not require hospital admission or 
blood transfusion) (Table 2).
Survival
A total of 12 patients in the pharmacotherapy–
EBL group died, as compared with 4 in the early-
TIPS group (P = 0.001). The 6-week survival rate was 
higher in the early-TIPS group than in the phar-
macotherapy–EBL group (97% vs. 67%; absolute 
risk reduction, 30 percentage points; 95% CI, 12 
to 48; number needed to treat, 3.3 patients; 95% CI, 
2.1 to 8.3), as was the 1-year survival rate (86% 
vs. 61%; absolute risk reduction, 25 percentage 
points; 95% CI, 2 to 48; number needed to treat, 
4.0 patients; 95% CI, 2.1 to 50.0) (Fig. 2). Causes 
of death are summarized in Table 2.
Other Complications of Portal Hypertension
The 1-year actuarial probability of hepatic enceph-
alopathy was 28% in the early-TIPS group as com-
pared with 40% in the pharmacotherapy–EBL 
group (an absolute difference of 12 percentage 
points; 95% CI, −18 to 40; P = 0.13). In the phar-
macotherapy–EBL group, 12 patients had a total 
of 17 episodes of hepatic encephalopathy, where-
as in the early-TIPS group, 8 patients had a total 
of 10 episodes (Table 3). Most of these episodes 
occurred during the index bleeding. After dis-
charge, the 1-year probability of additional epi-
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Figure 2. Actuarial Probability of the Primary Composite End Point and of Survival, According to Treatment Group.
The probability of remaining free from uncontrolled variceal bleeding or variceal rebleeding is shown in Panel A, and the probability of 
survival is shown in Panel B. EBL denotes endoscopic band ligation, and TIPS transjugular intrahepatic portosystemic shunt.
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sodes of hepatic encephalopathy was similar in 
the two groups (10% in the pharmacotherapy–EBL 
group and 19% in the early-TIPS group, P = 0.80). 
A total of 3 patients in the pharmacotherapy–EBL 
group and 2 in the early-TIPS group had stage III 
hepatic encephalopathy, and 1 patient in each 
group had mild, recurrent hepatic encephalopathy.
The 1-year actuarial probability of new or wors-
ening ascites was 33% in the pharmacotherapy–
EBL group and 13% in the early-TIPS group — an 
absolute difference of 20 percentage points (95% 
CI, −8 to 47; P = 0.11). Spontaneous bacterial peri-
tonitis developed during the index bleeding in 
2 patients in the pharmacotherapy–EBL group, 
both of whom died. In addition, the hepatorenal 
syndrome developed during the index bleeding in 
7 patients: 5 in the pharmacotherapy–EBL group, 
4 of whom died, and 2 in the early-TIPS group, 
both of whom survived. The proportion of fol-
low-up time that patients spent in the hospital was 
15% (interquartile range, 5 to 100) in the phar-
macotherapy–EBL group as compared with 4% 
(interquartile range, 2 to 13) in the early-TIPS 
group (P = 0.01).
Other Adverse Events
As shown in Table 3, there were no significant 
between-group differences in the numbers of pa-
tients who had adverse effects.
Discussion
In the study by Monescillo et al.,12 early treat-
ment with TIPS, as compared with medical treat-
ment, was associated with an improved progno-
sis among patients at high risk for uncontrolled 
bleeding or rebleeding on the basis of a hepatic 
venous pressure gradient of 20 mm Hg or higher.11 
This study did not include continued pharmaco-
logic therapy and EBL in the medical-treatment 
group, and bare stents were used in the early-TIPS 
group.12 The use of e-PTFE–covered stents is as-
sociated with reductions in the incidence of TIPS 
dysfunction and recurrence of complications re-
lated to portal hypertension.20,21 More important, 
the decision to perform TIPS was based on the 
measurement of hepatic venous pressure gradients, 
a test that is not widely available, especially under 
emergency conditions. Therefore, it is difficult to 
extrapolate the results of this study for applica-
tion to clinical practice.
Our study was specifically designed to show 
whether an early decision to use TIPS, with 
e-PTFE–covered stents and based on clinical cri-
teria, can improve the prognosis for patients with 
variceal bleeding who are at high risk. We found 
that in patients treated early with TIPS, the risks 
of failure to control bleeding and of variceal re-
bleeding were reduced.
In addition, and even more important, the early 
use of TIPS was associated with a reduction in 
mortality. This beneficial effect on survival was 
observed even though rescue TIPS was used in 
patients in whom medical treatment failed. Mor-
tality was very high among the patients who un-
derwent rescue TIPS after treatment failure, a re-
sult that is consistent with the findings in previous 
Table 3. Adverse Events.*
Adverse Event
Pharmacotherapy– 
EBL Group (N = 31)
Early-TIPS  
Group (N = 32)
no. of patients
Complications of portal hypertension
Hepatic encephalopathy 12 8
Ascites 9 5
Spontaneous bacterial peritonitis 2 0
Hepatorenal syndrome 5 2
Other serious adverse events
Infections (other than pneumonia or 
spontaneous bacterial peritonitis)
4 4
Pneumonia 3 3
Acute episode in chronic liver failure 1 3
Delirium tremens 2 1
Korsakoff syndrome 0 1
Esophageal perforation 1 0
Dysphagia 1 0
Bleeding from banding-related ulcers 1 0
Choledocholithiasis 0 1
Alcoholic hepatitis 0 1
Bleeding duodenal ulcer 0 1
Nonserious adverse events
Gynecomastia 0 1
Edema 1 0
Sleep disorder 1 0
Chest pain (after EBL) 1 0
Epistaxis (after EBL) 1 0
Vomiting 1 0
* EBL denotes endoscopic band ligation.
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studies.9,22 Remarkably, in five patients, TIPS was 
not even considered because of the severe deterio-
ration in liver function, as evidenced by the in-
creased MELD scores, which were higher than 
those associated with excessive mortality after 
TIPS.23 These data make it clear that for patients 
in Child–Pugh class C or in class B with active 
variceal bleeding, failure to initially control the 
bleeding or early rebleeding contributes to further 
deterioration in liver function, which in turn wors-
ens the prognosis and may preclude the use of 
rescue TIPS.
Previous studies evaluating the role of TIPS in 
the prevention of recurrent variceal bleeding clear-
ly showed that TIPS reduces the rebleeding rate 
but increases hepatic encephalopathy without im-
proving survival.24-26 Because of these findings, 
TIPS is currently recommended only as a rescue 
therapy.4,5 The results of the present study chal-
lenge this recommendation. It should be noted 
that previous studies of TIPS differed from our 
study in that they used bare stents or did not limit 
enrollment to patients at high risk for treatment 
failure. In the study by Escorsell et al.,26 more than 
15% of patients with variceal bleeding were ex-
cluded because of a need for emergency TIPS or 
death from uncontrolled bleeding before day 5. 
Therefore, the study design precluded the possi-
bility of demonstrating a benefit of TIPS in these 
high-risk patients. Furthermore, in another study,7 
mortality was 66% among patients whose bleed-
ing was not controlled by the initial treatment. 
In high-risk patients, the potentially deleterious 
effects of e-PTFE–covered TIPS appear to be coun-
terbalanced by its high efficacy in controlling 
bleeding and thus preventing further clinical de-
terioration. In contrast, TIPS should not be used 
as the initial treatment in patients with Child–
Pugh class A disease, since the rates of medical-
treatment failure and mortality are low among 
such patients.
Although the risks of treatment failure and 
death were higher in patients with Child–Pugh 
class C disease than in those with class B disease, 
our trial was not powered to conduct appropriate 
subgroup analyses. Therefore, further evaluation 
will be needed to determine whether the early use 
of TIPS equally benefits these two subgroups of 
patients.
The early use of TIPS was not associated with 
an increase in the number or severity of episodes 
of hepatic encephalopathy.
In conclusion, in patients with Child–Pugh 
class C disease or class B disease with active bleed-
ing who were admitted for acute variceal bleeding, 
the early use of TIPS with an e-PTFE–covered 
stent was associated with significant reductions 
in the failure to control bleeding, in rebleeding, 
and in mortality, with no increase in the risk of 
hepatic encephalopathy.
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